Analyst Price Targets — HROW
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 18, 2026 4:00 pm | Thomas Shrader | BTIG | $63.00 | $34.68 | StreetInsider | BTIG Reiterates Buy Rating on Harrow Health (HROW) ahead of presentations |
| March 4, 2026 11:41 am | Yi Chen | H.C. Wainwright | $70.00 | $39.62 | StreetInsider | Harrow Health (HROW) PT Raised to $70 at H.C. Wainwright |
| November 11, 2025 7:51 pm | — | Cantor Fitzgerald | $94.00 | $38.74 | TheFly | Cantor Fitzgerald reiterates Overweight rating on Harrow, ups target to $94 |
| September 29, 2025 12:36 pm | Thomas Flaten | Lake Street | $70.00 | $47.10 | TheFly | Harrow price target raised to $70 from $42 at Lake Street |
| September 23, 2025 12:59 pm | Chase Knickerbocker | Craig-Hallum | $64.00 | $48.93 | TheFly | Harrow price target raised to $64 from $54 at Craig-Hallum |
| August 13, 2025 10:18 am | Yi Chen | H.C. Wainwright | $64.00 | $34.83 | TheFly | Harrow price target raised to $64 from $60 at H.C. Wainwright |
| July 11, 2025 12:00 pm | Steve Seedhouse | Cantor Fitzgerald | $76.00 | $34.93 | TheFly | Harrow initiated with an Overweight at Cantor Fitzgerald amid path to growth |
| October 18, 2024 6:10 am | Sahil Kazmi | B.Riley Financial | $73.00 | $56.41 | StreetInsider | Harrow Health (HROW) PT Raised to $73 at B.Riley |
| October 4, 2024 8:41 am | Brooks O'Neil | Lake Street | $55.00 | $49.75 | TheFly | Harrow price target raised to $55 from $45 at Lake Street |
| August 9, 2024 10:36 am | Chase Knickerbocker | Craig-Hallum | $45.00 | $35.25 | TheFly | Harrow price target raised to $45 from $30 at Craig-Hallum |
Latest News for HROW
NASHVILLE, Tenn., April 16, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that IOPIDINE® 1% (apraclonidine hydrochloride ophthalmic solution) has been assigned a permanent J-Code (J2374) by the Centers for Medicare & Medicaid Services (CMS).
OLIVE BRANCH, Miss., April 14, 2026 /PRNewswire/ -- LogiCare3PL today announced it has been selected by Harrow, Inc. (Nasdaq: HROW) as a distribution partner for Harrow's portfolio of ophthalmic disease management solutions.
Harrow is rated a 'Strong Buy' with a fair value of $73.25, implying 104% upside from current levels (~$35.90). I project robust long-term growth driven by Vevye, Iheezo, and pipeline assets, despite recent short-term guidance disappointment and market volatility. I model a bit conservatively, with peak sales, a 32–45% EBIT margin for 2029–2035, and an 11.3% WACC, giving undervaluation even under some risk scenarios.
On April 13, 2026, Harrow Inc (HROW) shares rose 3.3% to a current price of $37.10. This price movement is situated within a 52-week range of $21.12 to $54.85,
JPMorgan Chase and Co. lowered its position in Harrow, Inc. (NASDAQ: HROW) by 53.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,167 shares of the company's stock after selling 42,246 shares during the quarter. JPMorgan Chase and Co. owned
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HROW.
U.S. House Trading
No House trades found for HROW.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.